|
|
Baxter International Inc (NYSE: BAX) |
|
Price: $25.8300
$0.26 
1.017%
|
| Day's High:
| $26.114999771118164
| Week Perf:
| -0.65 %
|
| Day's Low: |
$ 25.28 |
30 Day Perf: |
-4.37 % |
| Volume (M): |
3,413,684 |
52 Wk High: |
$ 30.00 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$20.65 |
| Open: |
$25.33 |
52 Wk Low: |
$15.73 |
|
|
| Market Capitalization (Millions $) |
13,302 |
| Shares
Outstanding (Millions) |
515 |
| Employees |
37,500 |
| Revenues (TTM) (Millions $) |
11,320 |
| Net Income (TTM) (Millions $) |
-1,098 |
| Cash Flow (TTM) (Millions $) |
-277 |
| Capital Exp. (TTM) (Millions $) |
528 |
Business Description
Baxter International Inc. is a global healthcare company that specializes in the development, manufacturing, and distribution of medical products and devices. The company offers a wide range of products, including pharmaceuticals, biotechnology therapies, and renal care solutions.
Baxter's products and therapies help treat various medical conditions, such as critical care, infectious diseases, kidney diseases, and immune disorders. The company is known for its innovative solutions that improve patient care and clinical outcomes.
Headquartered in Deerfield, Illinois, Baxter operates in over 100 countries and serves healthcare professionals and patients worldwide. The company has a strong focus on research and development, continuously investing in new technologies and therapies to address unmet medical needs.
Overall, Baxter International Inc. is committed to enhancing patient care, improving the quality of life, and advancing healthcare through its products and services.
Company Address: One Baxter Parkway, Deerfield, 60015 IL
Company Phone Number: 948.2000 Stock Exchange / Ticker: NYSE BAX
|
|
|
Customers Net Income fell by |
BAX's Customers Net Profit Margin fell to |
-31.22 % |
7.03 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Fri, Nov 7 2025 3:55 PM UTC
In a significant move to bolster educational opportunities in the Chicagoland area, the Baxter Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), recently announced a $2.6 million grant to Northwestern University s School of Education and Social Policy. This partnership is set to enhance science, technology, engineering, and math (STEM) education for ...
|
| Announcement
Published Mon, Oct 20 2025 8:41 AM UTC
In a pivotal announcement that has captured the attention of the investment community, the Rosen Law Firm an esteemed name in investor rights has filed a class action lawsuit against Baxter International Inc. (NYSE: BAX) on behalf of shareholders. This legal maneuver opens a significant chapter in a narrative marked by declining stock performance for Baxter, which has strugg...
|
| Business Update
Published Fri, Apr 11 2025 6:48 AM UTC
Baxter Expands Surgical Innovations with Room Temperature Stable Hemopatch, Amidst Revenue Challenges for Corporate Clients Baxter International Inc. Introduces Room Temperature Stable Hemopatch Hemostat: Innovations in Surgical Practice Amidst Corporate Revenue Fluctuations In a bold move to enhance surgical outcomes, Baxter International Inc. (NYSE: BAX), a globally recog...
|
| Business Update
Published Tue, Mar 4 2025 8:22 PM UTC
The Future of Healthcare Communication: Baxter s Transformative Leap with Voalte Linq In an era where efficient communication can dramatically influence patient care outcomes, Baxter International Inc. (NYSE:BAX), a leading force in the global medical technology landscape, has taken a pioneering step at the forefront of healthcare innovation, unveiling its groundbreaking Vo...
|
| Business Update
Published Wed, Dec 11 2024 2:47 PM UTC
In a remarkable showcase of growth within its pharmaceuticals division, Baxter International Inc. (NYSE:BAX) recently announced the launch of five new injectable products in the U.S. This development adds to the five launches introduced in April, culminating in a total of ten new injectable products this year. Baxter has established itself as a leader in the injectables sect...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-2.14 $ |
| Revenues (TTM) |
21.98 $
|
| Cash Flow (TTM) |
- |
| Cash |
3.92 $
|
| Book Value |
11.68 $
|
| Dividend (TTM) |
0.36 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
301,867 |
| Net
Income per Employee (TTM) |
-29,280 |
| Receivable Turnover Ratio (TTM) |
6.37 |
| Inventory Turnover Ratio (TTM) |
3.37 |
| Asset Turnover Ratio (TTM) |
0.56 |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.14 $
|
| Revenues (TTM) |
21.98 $ |
| Cash Flow (TTM) |
- |
| Cash |
3.92 $
|
| Book Value |
11.68 $ |
| Dividend (TTM) |
0.36 $ |
|
|
| |
| 2022 |
|
 0.19 % |
of total Revenue |
| 2023 |
|
0.19 % |
of total Revenue |
| 2024 |
|
0.33 % |
of total Revenue |
| 2025 |
|
0.3 % |
of total Revenue |
| 2026 |
|
0.11 % |
of total Revenue |
| United States |
|
53.13 % |
of total Revenue |
| International |
|
46.87 % |
of total Revenue |
| Medical Products Therapies |
|
47.57 % |
of total Revenue |
| Healthcare Systems Technologies |
|
26.1 % |
of total Revenue |
| Pharmaceuticals |
|
22.99 % |
of total Revenue |
| United States Medical Products Therapies |
|
25.58 % |
of total Revenue |
| United States Healthcare Systems Technologies |
|
18.99 % |
of total Revenue |
| United States Pharmaceuticals |
|
6.66 % |
of total Revenue |
| International Medical Products Therapies |
|
21.99 % |
of total Revenue |
| International Healthcare Systems Technologies |
|
7.11 % |
of total Revenue |
| International Pharmaceuticals |
|
16.33 % |
of total Revenue |
| Infusion Therapies Technologies Medical Products Therapies |
|
36.32 % |
of total Revenue |
| Infusion Therapies Technologies United States Medical Products Therapies |
|
19.47 % |
of total Revenue |
| Infusion Therapies Technologies International Medical Products Therapies |
|
16.85 % |
of total Revenue |
| Advanced Surgery Medical Products Therapies |
|
11.26 % |
of total Revenue |
| Advanced Surgery United States Medical Products Therapies |
|
6.11 % |
of total Revenue |
| Advanced Surgery International Medical Products Therapies |
|
5.15 % |
of total Revenue |
| Care Connectivity Solutions Healthcare Systems Technologies |
|
16.11 % |
of total Revenue |
| Care Connectivity Solutions United States Healthcare Systems Technologies |
|
11.66 % |
of total Revenue |
| Care Connectivity Solutions International Healthcare Systems Technologies |
|
4.44 % |
of total Revenue |
| Front Line Care Healthcare Systems Technologies |
|
10 % |
of total Revenue |
| Front Line Care United States Healthcare Systems Technologies |
|
7.33 % |
of total Revenue |
| Front Line Care International Healthcare Systems Technologies |
|
2.67 % |
of total Revenue |
| Injectables Anesthesia Pharmaceuticals |
|
11.14 % |
of total Revenue |
| Injectables Anesthesia United States Pharmaceuticals |
|
6.66 % |
of total Revenue |
| Injectables Anesthesia International Pharmaceuticals |
|
4.48 % |
of total Revenue |
| Drug Compounding Pharmaceuticals |
|
11.85 % |
of total Revenue |
| Drug Compounding International Pharmaceuticals |
|
11.85 % |
of total Revenue |
| Other |
|
3.33 % |
of total Revenue |
| Other United States |
|
1.89 % |
of total Revenue |
| Other International |
|
1.44 % |
of total Revenue |
| |
On February 20 2025 the Baxter International Inc provided following guidance
nnBaxter International Inc. Reports Financial Results for Q4 and Full Year 2024, Outlines 2025 Guidancenn
nnDEERFIELD, Ill. – February 20, 2025nn – Baxter International Inc. (NYSE: BAX), a renowned leader in the global medtech industry, has today announced its financial results for the fourth quarter and the entire year ended December 31, 2024. In conjunction with these results, the company has also provided its financial guidance for the first quarter and the full fiscal year 2025.
Brent Shafer, the chair and interim chief executive officer of Baxter, commented on the company’s performance, stating, Our results from 2024 and the strategic milestones we achieved underscore Baxter's gr...
|
|
|
2.05%